Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

Chronic Obstructive Pulmonary Disease Clinical Trial

— GLOW8  

Official title:

A 26-week Multi-center Randomized Double-blind Study to Compare Efficacy and Safety of NVA237 Versus Placebo as an add-on to Maintenance Therapy With Fixed-dose Combination Salmeterol/Fluticasone Propionate in COPD Patients With Moderate to Severe Airflow Limitation

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01757015
• Other study ID #: CNVA237A2311
• Secondary ID: 2012-002854-21
• Status: Withdrawn
• Phase: Phase 3
• First received: December 17, 2012
• Last updated: April 19, 2017
• Start date: April 2013
• Est. completion date: April 2014

Study information

• Verified date: August 2013
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in symptomatic COPD patients with moderate to severe airflow limitation who are already receiving maintenance therapy with inhaled fixed-dose-combination of salmeterol/fluticasone propionate (50/500 µg) twice daily (b.i.d.) via multi-dose dry powder inhaler (MDDPI).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Current or ex-smokers who have a smoking history of at least 10 pack years (e.g., 10 pack years = 1 pack/day × 10 years, ½ pack/day × 20 years, etc.).

• COPD (Chronic Obstructive Pulmonary Disease) patients with moderate to severe airflow limitation (Spirometry classification: GOLD 2 or 3) at Visit 2:

• Post-bronchodilator FEV1 (Forced Expiratory Volume in one second) =30% and <60% of the predicted normal, and,

• Post-bronchodilator FEV1/forced vital capacity (FVC) <0.70

• Patients on maintenance treatment with fixed-dose combination of inhaled salmeterol and fluticasone propionate (50/500 µg) b.i.d. delivered via a proprietary MDDPI (multidose dry powder inhaler) device for at least 30 days prior to screening visit (Visit 1).

• Patients in category Gold B or D with a CAT (COPD Assessment Test) total score =10 at screening (Visit 1) and before randomization (Visit 3).

• Patients with a history of at least 1 moderate or severe COPD exacerbation within the previous year.

Exclusion Criteria:

• Pregnant or nursing (lactating) women

• Women of child-bearing potential, unless they are using effective methods of contraception during the study

• Patients with a history of long QT syndrome or whose QTc measured at run-in (Visit 2) (Fridericia method) is prolonged (>450 ms). (These patients cannot be re-screened.)

• Patients with evidence (upon visual inspection) of oropharyngeal candidiasis at baseline with or without treatment.

• Patients who have not achieved an acceptable spirometry result at run-in (Visit 2) in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria for acceptability and repeatability.

• Patients who have had a COPD exacerbation that required treatment with antibiotics or oral corticosteroids or hospitalization in the 6 weeks prior to screening (Visit 1).

• Patients who have had a respiratory tract infection within 4 weeks prior to screening (Visit 1).

• Patients requiring long term oxygen therapy prescribed for >12 hours per day.

• Patients with allergic rhinitis who use an H1 antagonist or intra-nasal corticosteroids intermittently. (Treatment with a stable dose or regimen is permitted.)

• Patients with concomitant pulmonary disease (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, or pulmonary hypertension), clinically significant bronchiectasis, or history of pulmonary lobectomy, lung volume reduction surgery, or lung transplantation.

• Patients with active pulmonary tuberculosis, unless confirmed by imaging to be no longer active.

Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• NVA237
NVA237 (50µg, o.d. via SDDPI) in the morning,
• Placebo to NVA237
Placebo to NVA237

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Trough Forced Expiratory Volume in 1 second (FEV1)	Comparison of NVA237 treatment versus placebo treatment in the trough FEV1 after 12 weeks of treatment	after 12 weeks of treatment
Secondary	Total score of St George's Respiratory Questionnaire for COPD patients (SGRQ-C).	Comparison of NVA237 treatment versus placebo treatment in terms of change in SGRQ-C after 26 weeks of treatment	26 weeks
Secondary	Trough Forced Expiratory Volume in 1 second (FEV1)	Comparison of effect of NVA237 treatment versus placebo treatment in FEV1 after 4 weeks and after 26 weeks of treatment	week 4 , week 26
Secondary	Total score of the Transition Dyspnea Index (TDI)	Comparison of effect of NVA237 treatment versus placebo treatment in the total TDI score after 12 weeks and after 26 weeks of treatment	Week 12 and week 26
Secondary	Assessment of safety and tolerability	All safety endpoints will be summarized for the safety set.	26 Weeks